All clinical trials are reviewed by an Institutional Review Board (IRB) to protect the rights and safety of people who join. But some trials stand out because they’re doing more for patients. Our volunteer review committee helps identify some trials that are going above and beyond. They are our featured trials.
Clinical trials submitted to be featured will be scored on these categories:
- High Impact – Reviewers consider the potential impact on clinical practice, whether the research addresses a known issue or gap in care and more.
- Patient-Centered – Reviewers consider if travel costs for participants are paid for, if the informed consent is written in plain language, if results are shared with participants and more.
- Diversity, Equity and Inclusion Focus – Reviewers consider if the clinical trial staff are trained on cultural and anti-bias practices, the trial locations are in rural and urban areas and more.
- Accessibility – Reviewers consider if the eligibility criteria is as broad as possible, the requirements of participants seem reasonable for what they’re trying to study (e.g. there aren’t unnecessary labs or visits required), the number of trial locations and more.
Learn more about the process to have a clinical trial featured.
Trials featured beginning October 2024:
Trials featured beginning October 2024:
Previously featured trials:
- Allogeneic (cells from a donor) blood or marrow transplant (BMT) using cells from a deceased donor to treat acute leukemia
- A drug, belumosudil, to treat chronic graft-versus-host disease (GVHD) in children, teens and young adults
- Two drugs, isatuximab and lenalidomide, to treat multiple myeloma that doctors consider high-risk after autologous (your own cells) blood or marrow transplant (BMT)
- A drug, SER-155, alone or with the drug vancomycin, to prevent infection and graft-versus-host disease (GVHD) after allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Allogeneic (cells from a donor) blood or marrow transplant (BMT) and immunosuppressive therapy to treat severe aplastic anemia (SAA) that has not yet been treated in children, teens and young adults
- Cytokine-induced memory-like (CIML) natural killer (NK) cells from a haploidentical (half-matched) donor, to treat acute myeloid leukemia (AML) that has come back (relapsed) or has not gotten better with treatment (refractory)
- A drug, ravulizumab, compared to cemdisiran and pozelimab, to treat paroxysmal nocturnal hemoglobinuria (PNH)
- A drug, apraglutide, to treat acute graft-versus-host disease (GVHD) that has not gotten better with treatment (refractory)
- Engineered donor graft (donor cells treated in lab) for people getting allogeneic (cells from a donor) blood or marrow transplant (BMT) to treat blood cancer
- A drug, itolizumab, in combination with steroids, to treat acute graft-versus-host disease (GVHD)
- A drug, MT-401 (zedenoleucel), to treat acute myeloid leukemia (AML)
- A drug, REGN7257, to treat severe aplastic anemia (SAA) that has come back (relapsed) or has not gotten better with treatment (refractory)
- Viral specific T cells (VSTs), posoleucel (ALVR105), to prevent viral infections after an allogeneic (cells from a donor) blood or marrow transplant (BMT) in children and adults
- Viral specific T cells (VSTs), posoleucel, to treat adenovirus infection after an allogeneic (cells from a donor) blood or marrow transplant (BMT) in children and adults
- Viral specific T cells (VSTs), posoleucel, to treat virus-associated hemorrhagic cystitis (HC) after an allogeneic (cells from a donor) blood or marrow transplant (BMT) in children and adults
- Allogeneic (cells from a donor) blood or marrow transplant (BMT) with an unrelated mismatched donor and post-transplant cyclophosphamide (PTCy) to treat blood cancers in children and adults
- Gene therapy, using T cells (HA-1 TCR) from a donor, to treat acute leukemia that has come back (relapsed) after getting an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- CAR T cells (CD33CART) to treat acute myeloid leukemia (AML) that has come back (relapsed) or has not gotten better with treatment (refractory) in children and young adults
- Donor Search Prognosis (DSP) score to help choose the best donor before allogeneic (cells from a donor) blood or marrow transplant (BMT)
The content on this website is provided for informational purposes only. It is not intended to replace professional medical advice. Always seek the advice of your physician, or other qualified health care providers working with your physician, with questions you may have regarding any medical condition or your suitability for a particular clinical trial. The content of this website is not intended to be relied on for medical diagnosis or treatment.
Any specific diagnostic or therapeutic procedures, or treatment modalities including, but not limited to medications or products that may be mentioned on the site, are neither endorsed nor recommended by Be The Match. Be The Match does not assume any liability for the contents of any material provided on the site. Reliance on any information provided on this site is solely at your own risk. Be The Match accepts no liability or responsibility for damages or injuries arising from use of any product, information, idea, or instruction contained in the materials above.